Гепанты для купирования приступов мигрени
https://doi.org/10.30629/2658-7947-2022-27-3-5-10
Аннотация
В обзоре представлен механизм действия нового класса таргетных препаратов для лечения мигрени антагонистами рецепторов кальцитонин-ген-родственного пептида — гепантов. В настоящее время два препарата — уброгепант и римегепант — одобрены в США для купирования острых приступов мигрени. В РФ пока ни один из препаратов этого нового класса не зарегистрирован, однако это возможно в ближайшем будущем. Приведены результаты рандомизированных клинических исследований, продемонстрировавшие их эффективность по сравнению с триптанами и плацебо, а также хорошую переносимость и безопасность. Римегепант и уброгепант вызывают минимальные нежелательные эффекты и безопасны для людей с сердечно-сосудистыми заболеваниями. Гепанты могут представлять альтернативу для пациентов с мигренью, которые не могут применять триптаны из-за плохой их переносимости.
Об авторах
И. С. Ядгаров
Андижанский государственный медицинский институт
Узбекистан
Узбекистан
Андижан
Е. Г. Филатова
Первый Московский государственный медицинский университет им. И.М. Сеченова МЗ РФ (Сеченовский Университет)
Россия
Россия
Филатова Елена Глебовна —
Москва
В. Л. Голубев
Первый Московский государственный медицинский университет им. И.М. Сеченова МЗ РФ (Сеченовский Университет)
Россия
Россия
Москва
А. В. Бердникова
Первый Московский государственный медицинский университет им. И.М. Сеченова МЗ РФ (Сеченовский Университет)
Россия
Россия
Москва
Список литературы
1. Копишинская С.В., Густов А.В. Генетические аспекты мигрени. Журнал неврологии и психиатрии им. С.С. Корсакова. 2015;115(7):124–129. [Kopishinskaja S.V., Gustov A.V. Genetic aspects of migraine. Journal of Neurology and Psychiatry. 2015;115(7):124–129. (In Russ.)]. https://doi.org/10.17116/jnevro201511571124-129
2. Табеева Г.Р. Головная боль. Руководство для врачей. М.: Гэотар-медиа, 2018. [Tabeeva G.R. Headache. Guideline for doctors. M.: Geotar-media, 2018. (In Russ.)]. http://catalog.geotar.ru/lots/NF0009525.html
3. Hamelsky S., Stewart F., Lipton R. Epidemiology of migraine. Curr Pain Headache Rep. 2001;5:189–194. https://doi.org/10.1007/s11916-001-0088-9
4. Lipton R., Bigal M. The epidemiology of migraine. Am J Med. 2005;118(1):3–10. https://doi.org/10.1016/j.amjmed.2005.01.014
5. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age–sex specific all-cause and causespecific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385:117–171. https://doi.org/10.1016/S0140-6736(14)61682-2
6. Viana M., Sances G., Linde M., Ghiotto N., Guaschino E., Allena M., Terrazzino S., Nappi G., Goadsby J., Tassorelli C. Clinical features of migraine aura: result from a prospective diaryaided study. Cephalalgia. 2017;37(10):979–989. https://doi.org/10.1177/0333102416657147
7. Gajria K., Lee L.K., Flores N.M., Aycardi E., Gandhi S.K. Humanistic and economic burden of nausea and vomiting among migraine sufferers. J Pain Res. 2017;10:689–698. https://doi.org/10.2147/JPR.S124683
8. Ferrari M.D., Goadsby P.J., Roon K.I., Lipton R.B. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22(8):633–658. https://doi.org/10.1046/j.1468-2982.2002.00404.x
9. Geraud G., Keywood C., Senard J.M. Migraine headache recurrence:relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache. 2003;43(4):376– 388. https://doi.org/10.1046/j.1526-4610.2003.03073.x
10. Negro A., Martelletti P. Chronic migraine plus medication overuse headache: two entities or not? J Headache Pain. 2011;12(6):593–601. https://doi:10.1007/s10194-011-0388-3
11. Hong P., Tan T., Liu Y., Xiao J. Gepants for abortive treatment of migraine: A network meta-analysis. Brain Behav. 2020;10(8):e01701. https://doi.org/10.1002/brb3.1701
12. Villalon C.M., Olesen J. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol Ther. 2009,124(3):309– 322. https://doi.org/10.1016/j.pharmthera.2009.09.003
13. Edvinsson L., Warfvinge K. Recognizing the role of CGRP and CGRP receptors in migraine and its treatment. Cephalalgia. 2019;39(3):366–373. https://doi.org/10.1177/0333102417736900.
14. Noseda R., Burstein R. Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, CSD, sensitization and modulation of pain. Pain. 2013;154(1):44–53. https://doi.org/10.1016/j.pain.2013.07.021
15. Азимова Ю.Э. Мигрень: современный взгляд на классификацию, патофизиологию и терапию. Медицинcкий совет. 2014;5:27–31. [Azimova Y.E. Migraine: modern view of the classification, pathophysiology and specific therapy. Medical Council. 2014;5:27–31. (In Russ.)]. https://doi.org/10.21518/2079-701X-2014-5-27-29
16. Pan K.S., Siow A., Hay D.L., Walker C.S. Antagonism of CGRP Signaling by Rimegepant at Two Receptors. Front Pharmacol. 2020;11:1240. https://doi.org/10.3389/fphar.2020.01240
17. Goadsby P.J., Holland P.R., Martins-Oliveira M., Hoffmann J., Schankin C., Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553–622. https://doi.org/10.1152/physrev.00034.2015
18. Дубенко О.Е. Кальцитонин-ген-связанный пептид при мигрени: патогенетический фактор и терапевтическая мишень (обзор). Международный неврологический журнал. 2018;2(96):71–77. [Dubenko O.E. Calcitonin gene-related peptide: pathogenetic factor and therapeutic target (review). International Neurological Journal. 2018;2(96):71–77. (In Russ.)]. http://dx.doi.org/10.22141/2224-0713.2.96.2018.130481
19. Kaiser E.A., Russo A.F. CGRP and migraine: could PACAP play a role too? Neuropeptides. 2013;47(6):451–461. https://doi.org/10.1016/j.npep.2013.10.010
20. Burstein R., Noseda R., Borsook D. Migraine: multiple processes, complex pathophysiology. J Neurosci. 2015;35(17):6619– 6629. https://doi.org/10.1523/JNEUROSCI.0373-15.2015
21. Negro A., Martelletti P. Gepants for the treatment of migraine. Expert Opin Investig Drugs. 2019;28(6):555–567. https://doi.org/10.1080/13543784.2019.1618830
22. Loder E., Tfelt-Hansen P. The emperor’s new gepants: are the effects of the new oral CGRP antagonists clinically meaningful? Headache. 2019;59(1):113–117. https://doi.org/10.1111/head.13444
23. Koulchitsky S., Fischer M.J.M., Messlinger K. Calcitonin generelated peptide receptor inhibition reduces neuronal activity induced by prolonged increase in nitric oxide in the rat spinal trigeminal nucleus. Cephalalgia. 2009;29(4):408–417. https://doi.org/10.1111/j.1468-2982.2008.01745.x
24. Fischer M.J.M., Koulchitsky S., Messlinger K. The nonpeptide calcitonin gene-related peptide receptor antagonist BIBN4096BS lowers the activity of neurons with meningeal input in the rat spinal trigeminal nucleus. J Neurosci. 2005;25(25):5877–5883. https://doi.org/10.1523/JNEUROSCI.0869-05.2005
25. Doods H., Hallermayer G., Wu D., Entzeroth M., Rudolf K., Engel W., Eberlein W. Pharmacological profile of BIBN4096BS,the first selective small molecule CGRP antagonist. Br J Pharmacol. 2000;129(3):420–423. https://doi.org/10.1038/sj.bjp.0703110
26. Conway C.M., Croop R., Dubowchik G.M., Coric V., Lipton R.B. Cardiovascular safety of rimegepant 75 mg in 3 randomized clinical trials and systematic evaluations from in vitro, ex vivo and in vivo nonclinical assays. Neurology. 2020;94(15Supplement):2141. https://n.neurology.org/content/94/15_Supplement/2141
27. Dodick D., Lipton R., Ailani J., Simgh R., Shewale A., Yu S., Viswanathan H. Ubrogepant, an Acute Treatment for Migraine, Improved Patient‐Reported Functional Disability and Satisfaction in 2 Single‐Attack Phase 3 Randomized Trials, ACHIEVE I and II. Headache. 2020;60(4):686–700. https://doi.org/10.1111/head.13766
28. Voss T., Lipton R., Dodick D., Dupre N., Ge J., Assaid C., Aurora S., Mishelson D. A phase IIb randomized, doubleblind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia. 2016;36:887–898. https://doi.org/10.1177/0333102416653233
29. Storer R.J., Akerman S., Goadsby P.J. Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol. 2004;42(7):1171–1181. https://doi.org/10.1038/sj.bjp.0705807
30. Xu F., Sun W.Network meta-analysis of calcitonin gene-related peptide receptor antagonists for the acute treatment of migraine. Front Pharmacol. 2019;10:795. https://doi.org/10.3389/ fphar.2019.00795
31. Moreno-Ajona D., Perez-Rodriguez A., Goadsby P.J. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment? Curr Opin Neurol. 2020;33(3):309–315. https://doi.org/10.1097/WCO.0000000000000806
32. Moreno-Ajona D., Perez-Rodriguez A., Goadsby P.J. Smallmolecule CGRP receptor antagonists. A new approach to the acute and preventive treatment of migraine. Med Drug Discov. 2020;7,100053. https://doi.org/10.1016/j.medidd.2020.100053
33. Chan T.L.H., Cowan R.P., Woldeamanuel Y.W. Calcitonin GeneRelated Peptide Receptor Antagonists (Gepants) for the Acute Treatment of Nausea in Episodic Migraine: A Systematic Review and Meta-Analysis. Headache. 2020;60(7):1489–1499. https://doi.org/10.1111/head.13858
34. Ailani J., Lipton R.B., Hutchinson S., Knievel K., Lu K., Butler M., Yu S.Y., Finnegan M., Severt L., Trugman J.M. LongTerm Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial. Headache. 2020;60(1):141–152. https://doi.org/10.1111/head.13682
35. Dodick D.W., Goadsby P.J., Lakkis H.,Lu K., Jakate A., Finegan M., Szegedi A., Trugman J.M. Ubrogepant Achieves onset of pain relief at 1 hour for the acute treatment of migraine. Headache. 2019;59(s1):P103. https://doi.org/10.1111/head.13549
36. Jakate A., Boinpally R., Butler M., Lu K., Womack K., McGeeney D., Periclou A. Singlе therapeutic doses of ubrogepant are not associated with a clinically relevant drug-drug interaction when co-administered with acetaminophen or naproxen. Headache. 2019;59(s1):P96. https://doi.org/10.1111/head.13549
37. Curto M., Capi M., Cipolla F., Cisale G Y., Martelletti P., Lionetto L. Ubrogepant for the treatment of migraine. Expert Opinion Pharmacother. 2020;21(7):755–759. https://doi.org/10.1080/14656566.2020.1721462
38. Marcus R., Goadsby P.J., Dodick D., Stock D., Manos G., Fischer T.Z. BMS- 927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, doseranging trial. Cephalalgia. 2014;34(2):114–125. https://doi.org/10.1177/0333102413500727
39. Croop R., Goadsby P.J., Stock D.A., Conway C.M., Forshaw M., Stock E.G., Coricc V., Lipton R.B. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebocontrolled trial. Lancet. 2019;394(10200):737–745. https://doi.org/10.1016/S0140-6736(19)31606-X
40. Johnston K., Popoff E., Deighton A., Dabirvaziri P., Harris L., Thiry A., Croop R., Coric V., L’Italien G., Moren J. Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis. Expert Rev Pharmacoecon Res. 2021;2:1–12. https://doi.org/10.1080/14737167.2021.1945444
41. Peters G.L., Hennessey E.K. Rimegepant: acute treatment for migraine headaches. Pain Manag. 2021;11(3):259–266. https://doi.org/10.2217/pmt-2020-0090
42. Gao B., Yang Y., Wang Z., Sun Y, Chen Z., Zhu Y., Wang Z. Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine: Evidence From Randomized Controlled Trials. Front Pharmacol. 2020;10:1577. https://doi.org/10.3389/fphar.2019.01577
43. Lipton R.B., Croop R., Stock E.G., Stock D.A., Morris B.A., Frost M., Dubowchik G.M., Conway C.M., Coric V., Goadsby P.J. Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine. N Engl J Med. 2019;381(2):142–149. https://doi.org/10.1056/NEJMoa1811090
44. Hutchinson S., Schim J., Lipton R., ThiryA., Morris B., Coric V., Croop R. Safety of Rimegepant 75mg in adults with migraine: no effects of age, sex, or race in 3 phase 3 trials. Headache. 2019;59(s1):P247LB. https://doi.org/10.1111/head.13549
45. Edvinsson L. Rimegepant oral disintegrating tablet for migraine. Lancet. 2019;394(10200):711–712. https://doi.org/10.1016/s0140-6736(19)31611-3
46. Rimegepant (Nurtec ODT) for acute treatment of migraine. JAMA. 2020;324(9):890–891. https://doi.org/10.1001/jama.2020.8493
47. Berman G., Croop R., Kudrow D., Halverson P., Lovegren M., Thiry A.C., Conway C.M., Coric V., Lipton R.B. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine. Headache. 2020;60(8):1734–1742. https://doi.org/10.1111/head.13930
Рецензия
Для цитирования:
Ядгаров И.С., Филатова Е.Г., Голубев В.Л., Бердникова А.В. Гепанты для купирования приступов мигрени. Российский неврологический журнал. 2022;27(3):5-10. https://doi.org/10.30629/2658-7947-2022-27-3-5-10
For citation:
Yadgarov I.S., Filatova E.G., Golubev V.L., Berdnikova A.V. Relief of migraine attack — hepants. Russian neurological journal. 2022;27(3):5-10. (In Russ.) https://doi.org/10.30629/2658-7947-2022-27-3-5-10
Просмотров: 8084
Послать статью по эл. почте 